Topic: fatty liver disease
Using an old Roche drug, Madrigal Pharmaceuticals has seen its stock soar 130% on its latest fatty liver disease trials data.
Scientists at Duke have identified a pathway in the liver that they believe could be manipulated to reduce the deposition of fat in the liver, as well as glucose regulation.
The round reunites some of the executives and investors who helped Dezima and Akarna to takeovers by Amgen and Allergan, respectively.
Metacrine is adding to this week's NASH talk after getting off a series B as it aims to combat the fatty liver disorder.
Madrigal Pharmaceuticals has seen some positive snapshot data coming out of its phase 2 fatty liver disease test using an old Roche drug.
In new phase 2 data published today, Gilead says a higher dose of its NASH drug saw statistically significant reductions in liver fat.
CymaBay has taken a look at its ongoing midstage test for its liver med seladelpar, and is happy with what it sees.
UCSD scientists are repurposing the anti-inflammatory drug amlexanox to treat Type 2 diabetes.
J&J has unveiled another clutch of deals and collaborations with industry and academia.
Novartis has bolstered its R&D portfolio for NASH, a progressive fatty liver disease tipped to become a $20 billion to $35 billion market in the coming years, with its second deal in a month.